Aktienanalyse zu Zymeworks Inc (ZYME)ZYMEZymeworks Inc

Zymeworks Inc. is a global biotechnology company building a diversified portfolio of healthcare assets. The Company's asset and royalty aggregation strategy combines a portfolio of commercial and near-commercial assets, including YUPELRI (revefenacin), with a differentiated internal research and development engine. The Company's portfolio also includes Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by it and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using the Company's proprietary antibody engineering technologies. The Company is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. Its product candidates include ZW191, ZW251, ZW220, ZW209 and ZW1528. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Zymeworks Inc is a good buy right now due to its current price of $25.03, which is significantly lower than the average analyst price target of $34, representing a potential upside of 35.5%. Additionally, the company has a gross margin of 100%, indicating strong profitability potential despite current losses. However, investors should be cautious of the high forward P/E ratio of 20.83, which suggests that the stock may be overvalued if earnings do not improve significantly in the near future.

4 analysts cover ZYME: 3 rate it Buy, 0 Hold and 1 Sell. The average price target is 35.55.